About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

No Harm Seen in Disclosing Genetic Risk for Alzheimer's Disease

by Rajashri on July 16, 2009 at 8:52 PM
 No Harm Seen in Disclosing Genetic Risk for Alzheimer's Disease

Disclosing genetic risk information to adult children of patients with Alzheimer's disease (AD) who request this information does not result in significant short-term psychological distress, researchers from Boston University School of Medicine (BUSM) have shown.

The report from the REVEAL Study*, which appears in the July 16 issue of the New England Journal of Medicine, is the first randomized trial to disclose to participants whether or not they carried the ε4 variant of the APOE gene, a variant that has been found to increase the risk of developing AD. The study demonstrated that test-related distress was reduced among those who learned that they were APOE ε4 negative, and was only transiently increased among those who learned they were APOE ε4 positive. The study also showed that persons with high levels of emotional distress before undergoing genetic testing were more likely to have emotional difficulties after disclosure.

Advertisement

The study comes at a time when gene variants that are associated with risks of common diseases are being rapidly discovered and genetic testing is now being marketed by direct-to-consumer genetics testing companies such as 23andMe, Navigenics and DeCodeMe. Considerable controversy has accompanied the launch of these companies and one area of concern has been the potential for psychological harm if individuals learn they are at increased risk for diseases that have no treatment, such as AD.

The BUSM researchers, along with their collaborators at the University of Michigan, Weill Cornell Medical College and Case Western Reserve University School of Medicine randomly assigned 162 asymptomatic adults who had a parent with Alzheimer's disease to two groups: the disclosure group, who received a risk assessment for their chance to develop AD that included their APOE genotyping results, and the nondisclosure group, who received a risk assessment for AD that excluded their APOE genotyping status. They then measured symptoms of anxiety, depression, and test-related distress six weeks, six months, and one year after disclosure or nondisclosure and found no significant differences between the two groups in measures of anxiety, depression or test-related distress.
Advertisement

Comparisons between the subgroup of participants carrying the APOE ε4 variant and those who did not learn their genotype revealed no significant differences, suggesting that learning about increased risk did not cause psychological harm. However, the ε4 negative subgroup had a significantly lower level of test-related distress than did the ε4 positive subgroup, suggesting a psychological benefit to those who learned they were at lower risk.

"Study participants who learned they were ε4 positive and were therefore at increased risk for Alzheimer's disease showed no more anxiety, depression, or test-related distress than those who did not learn their genotype," said lead author Robert C. Green, MD, MPH, a professor of neurology, genetics and epidemiology at BUSM as well as a fellow in genetics at Harvard Medical School, "but those who learned they were ε4 negative experienced considerable relief."

"It's important to recognize that our participants were carefully screened for pre-existing emotional problems and that trained genetic counselors disclosed the information," adds Green, "so it is not the same thing as simply providing risk information to anyone who asks. Nevertheless, our work supports the notion that learning genetic risk information can be a positive and empowering experience for some people, even when the disease is frightening and the genetic information has no clear medical benefit. "

According to the BUSM researchers, larger studies that follow participants for more than one year will be required to detect uncommon and long-term effects, such as delayed emotional repercussions and injudicious life decisions. These studies are currently underway in new REVEAL Study trials.



Source: Eurekalert
RAS
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Senior Health News

Digestive Issues Can Make Elderly More Prone To Loneliness, Depression
Digestive illnesses among older adults result in increased levels of loneliness and depression, which in turn have a detrimental effect on overall health.
Eye-Tracking Technology Empowers Dementia Patients With a Voice
Using eye-tracking technology in dementia care facilities improves online assessments, allowing older individuals to self-report on care and quality of life.
What is the Best Temperature for Better Sleep Quality in Older Adults?
Older individual's ability to sleep well is strongly influenced by the ambient night-time temperature minimizing aging-related health risks.
Unhealthy Lifestyle Increases Risk of Nursing Home Care
In individuals aged over 60, lifestyle factors are highly correlated with the likelihood of prolonged nursing home admission, at least within Australia.
Phytosterol Supplements To Fight Hearing Loss
Phytosterol supplements can replenish lost cholesterol and help mitigate age-related hearing loss.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

No Harm Seen in Disclosing Genetic Risk for Alzheimer's Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests